Business Context and Reporting Period
Company: Techne Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1997 (Third Quarter of Fiscal 1997)
Business Overview: The Company operates through two primary subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, and R&D Systems Europe Ltd. in Abingdon, England. Operations are divided into Biotechnology (cytokines, antibodies, assay kits) and Hematology (blood controls and calibrators) divisions.
Key Financial Metrics
| Metric | Quarter Ended 3/31/97 | Nine Months Ended 3/31/97 | Nine Months Ended 3/31/96 |
|---|---|---|---|
| Sales | $16,251,827 | $44,688,099 | $40,022,138 |
| Gross Margin | $11,272,073 (69.4%) | $30,358,503 (67.9%) | $25,706,969 (64.2%) |
| Net Earnings | $2,951,902 | $7,404,662 | $5,983,831 |
| Earnings Per Share (Diluted) | $0.30 | $0.76 | $0.62 |
| Cash & Equivalents | $5,391,305 | $19,598,342 (Total Cash & Short-term Investments) | |
| Short-term Investments | $14,207,037 | ||
| Total Assets | $48,638,980 | $44,393,293 (Prior Year End) | |
| Total Liabilities | $4,950,800 | ||
| Stockholders' Equity | $43,688,180 | $38,874,071 (Prior Year End) | |
| Operating Cash Flow (9mo) | $7,230,229 | $6,456,392 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 10% for the quarter and 12% for the nine-month period compared to the prior year. This was driven primarily by a 28% increase in biotechnology product sales (cytokines and antibodies).
- Margin Expansion: Gross margins improved significantly, rising from 65.9% to 69.4% for the quarter and from 64.2% to 67.9% for the nine-month period. This was attributed to a favorable product mix shift toward higher-margin biotechnology products and the cessation of royalty payments to Amgen Inc. in August 1996.
- Hematology Decline: Sales of hematology products decreased by $178,682 for the quarter and $805,299 for the nine months, largely due to the loss of an OEM customer at the end of the prior fiscal year.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 17% for the quarter, including a one-time restructuring charge of approximately $450,000 related to R&D Europe. R&D expenses increased 15% for the quarter due to new product development.
- Stock Repurchases: The Company repurchased 117,300 shares of common stock for $2,976,452 during the nine-month period, extending its repurchase program to an additional $5,000,000.
Guidance, Outlook, and Risks
- Restructuring: R&D Europe is undergoing a restructuring to withdraw from the molecular biology market and transfer marketing and manufacturing activities to R&D Systems by June 30, 1997. Sales functions in Europe remain unaffected.
- Capital Expenditures: Capital additions for the first nine months were $3.88 million, primarily for facility expansion and remodeling. Remaining planned expenditures for fiscal 1997 are estimated at approximately $1 million, to be funded by existing cash and operating flows.
- Liquidity: The Company maintains a strong liquidity position with over $19.5 million in cash and short-term investments. It holds an unsecured line of credit of $750,000, which remains undrawn.
- Risks: Key risks include the acceptance of new products, price competition in the cytokine market, retention of hematology OEM customers, and the impact of exchange rate fluctuations on European operations.
Investor Verification Checklist
- Restructuring Impact: Verify the execution of the R&D Europe restructuring and the associated $450,000 charge to ensure no further hidden costs.
- OEM Customer Loss: Assess the long-term impact of the lost hematology OEM customer and the success of efforts to replace it with retail and other OEM sales.
- Product Mix Sustainability: Confirm if the shift toward higher-margin biotechnology products is sustainable or if it masks underlying weakness in the hematology division.
- Stock Repurchase Program: Monitor the pace of the extended $5,000,000 stock repurchase program and its effect on share count and earnings per share.
- Foreign Exchange Exposure: Review the sensitivity of R&D Europe's financial results to fluctuations in the U.S. dollar/British pound exchange rate.